DCF Valuation

Guardian Pharmacy Services, Inc. (GRDN) DCF Valuation — Is GRDN overvalued?

The estimated DCF fair value of one Guardian Pharmacy Services, Inc. (GRDN) share is $37.28. Compared to the current market price of $43.83, the stock is overvalued by 14.9%.

DCF fair value

$37.28

Market price

$43.83

Upside / downside

−14.9%

Run the full interactive DCF model →

Prefer the inverse question? See what growth rate the market is pricing into GRDN

Guardian Pharmacy Services, Inc. (GRDN) DCF valuation FAQ

What is the DCF fair value of Guardian Pharmacy Services, Inc. (GRDN)?

The discounted-cash-flow model estimates the intrinsic fair value of one Guardian Pharmacy Services, Inc. (GRDN) share at $37.28, based on a 10-year projection of its cash flows converging to Damodaran industry averages.

Is Guardian Pharmacy Services, Inc. (GRDN) overvalued or undervalued?

Against the current market price of $43.83, the DCF fair value of $37.28 implies GRDN is overvalued by 14.9%.

How is the GRDN DCF value calculated?

It is a 10-year discounted-cash-flow estimate built from Guardian Pharmacy Services, Inc.'s reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Guardian Pharmacy Services, Inc. files a new quarterly or annual report.

How this GRDN valuation is built

The model projects ten years of Guardian Pharmacy Services, Inc.'s free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Guardian Pharmacy Services, Inc.'s ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.

WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.

The market price refreshes daily; the DCF fair value updates when Guardian Pharmacy Services, Inc. files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-08.